 PharmaceuticalsPeter Nolan
Chapter 5 in China and the Global Business Revolution, 2001, pp 241-326 from Palgrave Macmillan Abstract: Abstract This chapter analyzes the growth from scratch of one of the most powerful firms in the Chinese pharmaceutical industry, the Sanjiu Group. Analysis of this firm is interesting for several reasons. First, it sheds light on the importance of existing powerful institutions in shaping the emergence of big businesses in China’s reforming economy. Most of China’s emerging powerful large businesses are based on the ‘commanding heights’, ‘keypoint’ firms of the old planned economy. Unlike these firms, Sanjiu is a ‘new entrant’. However, it is a ‘new entrant’ with a difference, since the owners of the firm until the late 1990s were one of the most powerful institutions in China (some would say, the most powerful), namely the People’s Liberation Army (PLA). Until 1998 Sanjiu was owned by the General Logistics Department (GLD) of the PLA. In 1998, the central government announced that it intended to divorce the military from the commercial activities of the PLA. If fully implemented, this move would have major consequences for the institutional structure of wide areas of the Chinese economy. Keywords: Traditional Chinese Medicine; Sales Revenue; Pharmaceutical Firm; Patented Medicine; Patented Drug (search for similar items in EconPapers) There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it. Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-52410-1_5 Ordering information: This item can be ordered from Access Statistics for this chapter More chapters in Palgrave Macmillan Books from Palgrave Macmillan |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.